Psoriasis, an itchy skin ailment thought to have autoimmune origins, can result in a widespread, chronic, scaly rash. An estimated 7.5 million Americans have the disorder, which can be difficult to treat effectively. One treatment has been the Amgen, Inc., drug Otezla.
Bristol Myers Squibb Co. has come up with an alternative. In recent late-stage trials, after 16 weeks of treatment, patients who got the orally administered psoriasis drug deucravacitinib had far fewer and less severe psoriasis plaques than those who got a placebo. Many patients who got deucravacitinib had a 75% or greater improvement in their psoriasis on the Psoriasis Area Severity Index.
Deucravacitinib also was better at clearing moderate to severe psoriasis than Otezla. Results from a second late-stage trial of the drug are expected in the first quarter of 2021.
Shares of Bristol Myers Squibb jumped higher this week (3.85% on Tuesday) after the positive data were posted. Quarterly earnings should be out this week, and analysts seek $1.49 per share on revenues of $10.36 billion. The leading market treatment for psoriasis is Cosentyx, made by Novartis AG. Sales for all psoriasis treatment drugs are expected to grow by 9.5% annually to over $24 billion by 2023.
Disclaimer: This article does not provide medical advice. Do not take action based solely on this article and always consult with an appropriate healthcare professional. This article is purely for informational purposes.